APP and Alzheimer disease: For example, genetic engineering and co-transfection of parental cells are combined to create EVs that exhibit RVG peptide on their surface, target α7-nAChR, and enrich neutral lysozyme variants with higher specificity and beta-amyloid peptide (Aβ) degradation efficacy for the treatment of Alzheimer’s disease (AD) (Yu et al., 2021).